World Thalassaemia Day 2026: Finding the Undiagnosed and Supporting the Unseen

Every year on 8 May, the global thalassaemia community pauses to do something the condition itself rarely allows: make itself visible. Marked as World Thalassaemia Day, the day is not just about awareness, but about recognition of those who often remain undiagnosed, unsupported, or overlooked.

Thalassaemia is a genetic blood disorder that, in its severe forms, requires lifelong blood transfusions, regular monitoring, and specialised medical care. Yet many individuals are diagnosed with thalassaemia only during pregnancy or early childhood, at a stage when earlier screening and timely care could have significantly improved outcomes. What is even more concerning is that a large number of people carry this type of gene without even knowing about it, and when such two carriers have a child together, there is a possibility that the child (one in four) will inherit a severe form of the disease.

In India, the situation is no less concerning. The average prevalence of beta thalassaemia carriers is 3 to 4%, which translates to 35 to 45 million carriers in India’s multi-ethnic population. The estimated number of births of affected babies annually is between 10,000 and 12,000. These are not abstract figures, they are children, families, and communities living with a disease that is largely preventable through carrier screening, and manageable through timely, specialist care.

At RGCIRC (Rajiv Gandhi Cancer Institute and Research Centre), thalassaemia and related haemoglobin disorders are managed within the Haemato-Oncology and Bone Marrow Transplant programme. The institute has been at the forefront of advanced treatments in India, including unrelated donor transplants, matched unrelated donor (MUD) transplants, and stem cell transplantation. This World Thalassaemia Day, the focus is clear, which is to bring the unseen into view, strengthen early detection, and ensure that every individual receives the care and support they need.

What is World Thalassaemia Day?

World Thalassaemia Day, also referred to as International Thalassaemia Day, is observed every year on 8 May. It was established by the Thalassaemia International Federation (TIF), a global non-profit organisation founded in 1986 that represents over 240 national thalassaemia patient associations across 67 countries.

The day serves as a unified platform for patients, families, healthcare professionals, governments, and policymakers to raise awareness about thalassaemia, advocate for equitable access to diagnosis and treatment, and recognise the lived experiences of those managing the condition every day.

As one of India’s leading haematology and oncology centres, RGCIRC actively works to bridge this gap. Each year, the institute brings together its Haemato-Oncology specialists, patients, and communities through initiatives such as carrier screening camps, educational workshops, and interactive sessions led by treating doctors. These efforts aim to equip individuals and families with the knowledge, access, and confidence needed to take timely and informed decisions. Because in thalassaemia, early awareness is not just important; it can mean the difference between prevention and a lifetime of ongoing treatment.

World Thalassaemia Day 2026 Theme: Hidden No More

The official theme for International Thalassaemia Day 2026, announced by the Thalassaemia International Federation, is “Hidden No More: Finding the Undiagnosed. Supporting the Unseen.”

This theme brings attention to two closely linked realities shaping the global thalassaemia landscape today. The first is the large number of individuals who remain undiagnosed due to gaps in early screening. In many cases, thalassaemia is only identified during pregnancy or early childhood – stages where earlier detection could have significantly improved long-term outcomes.

The second reality is equally important: those already diagnosed but still living without adequate visibility, support, or access to consistent care. Many patients continue to face social stigma, limited awareness, and health systems that do not fully prioritise long-term management needs.

In India, both challenges are especially relevant. Carrier screening before marriage or pregnancy is still not uniformly practised, and access to regular blood transfusions, iron chelation therapy, and specialist haematology care remains uneven, particularly in smaller cities and rural areas. The 2026 theme calls for visibility at every level: individual awareness, institutional responsibility, and stronger public health policy.

Alongside this, the global Bring Thal to Light initiative encourages cities and landmarks worldwide to light up in red on 8 May as a symbol of solidarity. The message is simple but powerful: greater visibility leads to dignity, and dignity must lead to meaningful action.

What is Thalassaemia?

Thalassaemia is an inherited blood disorder in which the body produces insufficient or abnormal haemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. As a result, red blood cells become fragile, have a shorter lifespan, and are less effective at transporting oxygen. This leads to chronic anaemia, which in severe cases requires lifelong medical care and monitoring.

The condition is caused by mutations in the genes that control the production of haemoglobin’s protein chains, specifically the alpha and beta globin chains. Thalassaemia follows an autosomal recessive pattern of inheritance. This means a child must inherit a defective gene from both parents to develop the severe form of the disease.

If a child inherits only one defective gene, they become a carrier, known as having thalassaemia trait or thalassaemia minor. Carriers usually do not have significant symptoms, but they can pass the gene to their children, which is why awareness and screening are important.

Types of Thalassaemia

Thalassaemia is classified in two ways: by the globin chain affected (alpha or beta), and by the severity of the disease (major, intermedia, or minor). Understanding both dimensions is important for accurate diagnosis, genetic counselling, and treatment planning.

Alpha Thalassaemia

Alpha thalassaemia occurs due to mutations in the genes responsible for producing alpha globin chains. Each person has four such genes, and the severity depends on how many are affected.

• One or two gene deletions: Carrier state with mild or no anaemia
• Three gene deletions: Haemoglobin H disease, a moderate to severe condition that requires medical care
• Four gene deletions: Hydrops fetalis, a severe condition usually not compatible with life outside the womb

Alpha thalassaemia is more commonly seen in populations from South-East Asia, Africa, and the Mediterranean region.

Beta Thalassaemia

Beta thalassaemia results from mutations in the genes that produce beta globin chains. Each person has two such genes. This is the most clinically significant form of thalassaemia in India.

The condition is further classified based on severity:

• Thalassaemia Major: The most severe form, occurring when both beta globin genes are defective. Symptoms typically appear between 6 and 24 months of age, with severe anaemia requiring regular blood transfusions. Without treatment, survival beyond early childhood is unlikely. Long-term transfusion therapy can extend life but leads to iron overload, which requires ongoing chelation therapy.
• Thalassaemia Intermedia: A moderate form where some haemoglobin production is preserved. Patients may not need regular transfusions but may require them during periods of stress, illness, or growth. The clinical course varies from person to person.
• Thalassaemia Minor (Carrier State): Individuals with one normal and one defective gene are carriers. They usually have mild anaemia, often mistaken for iron deficiency, and lead normal lives without treatment. However, identification through screening is important, as two carriers have a one in four risk of having a child with thalassaemia major.

Signs, Symptoms, and Complications of Thalassaemia

The clinical presentation of thalassaemia varies widely depending on its type and severity. Individuals with thalassaemia minor are usually asymptomatic, while those with thalassaemia major develop significant symptoms early in life. The following are the key clinical features and long-term health concerns seen in moderate to severe thalassaemia.

Chronic Anaemia and Fatigue

Persistent anaemia is the defining feature of thalassaemia major. Due to reduced or ineffective haemoglobin, oxygen delivery to tissues remains inadequate. This leads to:

• Extreme fatigue and weakness
• Pallor
• Breathlessness on exertion
• Reduced ability to carry out daily activities

Without regular blood transfusions to maintain haemoglobin levels, children often experience poor growth and delayed development.

Bone Deformation and Growth Delays

To compensate for anaemia, the bone marrow increases red blood cell production. This expansion affects bone structure and strength.

• Changes in facial and skull bones, known as thalassaemic facies
• Weakened bones with increased risk of fractures
• Growth retardation in children
• Delayed puberty due to long-term systemic effects

Iron Overload and Organ Damage

Repeated blood transfusions introduce excess iron into the body. Since the body cannot naturally eliminate this excess, iron accumulates over time and affects vital organs.

• Progressive iron deposition in the heart, liver, and endocrine glands
• Increased risk of organ dysfunction
• Need for lifelong iron chelation therapy to prevent damage

Heart and Liver Complications

Iron overload has a direct impact on major organs, particularly the heart and liver.

• Cardiac effects: Cardiomyopathy, heart failure, and arrhythmias are leading causes of mortality in inadequately treated patients
• Liver effects: Progressive liver damage, fibrosis, and in some cases cirrhosis

Regular monitoring, including specialised imaging such as T2* MRI, is essential to assess iron levels and guide appropriate chelation therapy.

Causes, Inheritance, and Risk Factors of Thalassaemia

Understanding how thalassaemia develops and is passed on is essential for early identification and prevention. The condition is entirely genetic, which makes awareness and screening particularly important.

Genetic Inheritance

Thalassaemia is caused by inherited mutations in specific genes that control haemoglobin production.

• Beta thalassaemia: Mutation in the HBB gene
• Alpha thalassaemia: Mutations in the HBA1 and HBA2 genes

The condition follows an autosomal recessive inheritance pattern. This means a child must inherit one defective gene from each parent to develop thalassaemia major. If both parents are carriers, there is a risk of the child being affected.

Risk of Passing Thalassaemia to Children

When both parents are carriers of beta thalassaemia, each pregnancy carries the following probabilities:

• 25% chance: Child will have thalassaemia major
• 50% chance: Child will be a carrier
• 25% chance: Child will be unaffected

This predictable inheritance pattern makes carrier screening before marriage or pregnancy the most effective way to prevent severe forms of the disease.

Regions with Higher Prevalence in India

Carrier rates for thalassaemia vary across India and are influenced by regional and community factors.

• Higher prevalence has been observed in Punjab, Gujarat, Maharashtra, West Bengal, Odisha, and north-eastern states
• Certain ethnic groups show carrier rates ranging from 4% to 17%
• Carriers are present across all regions, not limited to specific states

Communities with higher rates of intra-community marriages have an increased likelihood of both partners being carriers, which raises the risk of having a child with thalassaemia major. This highlights the importance of widespread screening and genetic counselling across all populations.

Treatment and Management of Thalassaemia

There is no single universal cure for thalassaemia, but the condition can be effectively managed with appropriate medical care. In selected cases, it may be cured through advanced procedures such as bone marrow or stem cell transplantation. Treatment is typically long-term and requires a combination of medical therapies, monitoring, and supportive care.

Regular Blood Transfusions

Regular red blood cell transfusions form the backbone of treatment for thalassaemia major. They help maintain haemoglobin levels required for normal growth, organ function, and daily activity. Most patients require transfusions every two to four weeks throughout life. Careful blood matching and the use of leucocyte-depleted blood products help reduce the risk of transfusion reactions and long-term complications.

Iron Chelation Therapy

Because repeated transfusions introduce excess iron into the body, iron chelation therapy is essential. The body cannot naturally eliminate this excess iron, and if left untreated, it accumulates in vital organs such as the heart and liver. Chelating medications such as Deferoxamine, Deferasirox, and Deferiprone bind to excess iron and help remove it from the body. Treatment is guided by serum ferritin levels and imaging methods such as T2* MRI, which assess iron levels in organs. Adequate chelation is critical to preventing serious long-term complications.

Bone Marrow and Stem Cell Transplantation

Allogeneic bone marrow or haematopoietic stem cell transplantation is currently the only established curative option for thalassaemia major. This procedure replaces the patient’s defective bone marrow with healthy cells from a compatible donor, allowing normal haemoglobin production. Outcomes are best in younger patients with a matched sibling donor and minimal organ damage. Unrelated donor transplants are increasingly successful as transplant protocols continue to improve. At RGCIRC, the Bone Marrow Transplant Unit has contributed significantly to advancements in unrelated donor and matched unrelated donor transplants in India.

Gene Therapy

Gene therapy is an emerging and promising area in thalassaemia treatment. Instead of using donor cells, this approach aims to correct the genetic defect within the patient’s own cells. Betibeglogene autotemcel is the first approved gene therapy for beta thalassaemia and has shown the ability to reduce or eliminate the need for transfusions in some patients. Other approaches, including CRISPR-based gene editing, are under active development and may offer more accessible options in the future.

Lifestyle and Dietary Considerations

Supportive care is an important part of long-term management. Patients are advised to follow a balanced diet that supports overall health without increasing iron overload. Iron-rich foods such as red meat and organ meats should be consumed in moderation, particularly in regularly transfused patients. Vitamin C intake should be monitored when taken alongside iron-rich meals, as it enhances iron absorption. Adequate intake of calcium and Vitamin D is important to maintain bone health, and folic acid supplementation is often recommended to support red blood cell production. Maintaining hydration and avoiding alcohol are also important to protect liver function.

With consistent medical care, regular monitoring, and appropriate lifestyle measures, many individuals with thalassaemia can lead longer, healthier, and more active lives.

How Can Thalassaemia be Prevented?

Thalassaemia is one of the most preventable serious genetic disorders when timely screening and counselling are available. Prevention centres on early identification of carriers and informed decision-making before or during pregnancy.

Carrier Screening

Identifying carriers before they have children is the most effective preventive step. A simple blood test, including a complete blood count followed by haemoglobin electrophoresis or HPLC, can detect whether an individual carries the thalassaemia gene. When both partners are tested before marriage or conception, they are better equipped to understand their reproductive risk and plan accordingly.

Prenatal Diagnosis

If both partners are carriers, prenatal testing can determine whether the foetus is affected. This is done through chorionic villus sampling between 10 and 13 weeks of pregnancy or amniocentesis between 15 and 18 weeks. These decisions are made with the support of medical guidance and counselling, allowing families to fully understand the implications and available options.

Genetic Counselling

Genetic counselling is an essential part of prevention. It helps individuals and families understand how thalassaemia is inherited, what risks exist for future children, and what choices are available. This ensures decisions are based on clear, accurate information rather than uncertainty or fear.

National and Community-Level Screening Programmes

Countries such as Cyprus, Greece, and Italy have shown that organised national programmes can significantly reduce new thalassaemia cases. These programmes combine public awareness, routine screening, and access to prenatal diagnosis with counselling.

In India, where the burden remains high, strengthening similar large-scale initiatives is essential. The message of World Thalassaemia Day 2026 reinforces this need—early detection and systemic action are key to ensuring that fewer children are born with severe forms of thalassaemia.

Why Choose RGCIRC for Thalassaemia Care

RGCIRC has been delivering specialist haematology and cancer care since 1996 and is recognised among Asia’s leading exclusive cancer centres. For patients with thalassaemia, this depth of experience translates into a comprehensive care pathway that spans long-term transfusion support to potentially curative transplantation.

A Pioneering Bone Marrow Transplant Programme

RGCIRC’s dedicated 22-bedded Bone Marrow Transplant Unit is one of the most experienced in India and has played a key role in advancing unrelated donor and matched unrelated donor transplants in the country. For eligible patients with thalassaemia major, transplantation offers the possibility of cure and long-term transfusion independence. Each case is evaluated individually, with careful assessment of donor compatibility, disease severity, and overall organ health before proceeding.

Comprehensive Haematology and Supportive Care

Beyond transplantation, the Haemato-Oncology team provides continuous care across all stages of thalassaemia. This includes regular transfusion services with appropriate blood matching, close monitoring and optimisation of iron chelation therapy using serum ferritin levels and T2* MRI, as well as ongoing cardiac and endocrine evaluation to manage long-term effects. Nutritional guidance and psychological support are also integrated into patient care, ensuring a more holistic approach.

Advanced Technology and Recognised Standards of Care

RGCIRC was the first hospital in India to establish a molecular laboratory and among the early adopters of robotic surgery in oncology. The institute holds NABH (5th Edition) and NABL accreditations, along with Green OT and Nursing Excellence certifications. It has been recognised among the World’s Best Specialised Hospitals by Newsweek in 2024 and 2025, ranked No. 1 in North India for single-specialty hospitals by The Times of India in 2025, and awarded Best Oncology Hospital of the Year 2026 by the IHW Council.

Commitment Beyond Treatment

As a not-for-profit institution, RGCIRC extends financial support through its Philanthropy Department to patients who require assistance. This ensures that access to quality thalassaemia care is not limited by financial constraints. Since its inception, the institute has supported over 3.5 lakh patients from across India and the SAARC region, reflecting its continued commitment to accessible and patient-centred care.

Book a Consultation at RGCIRC

If your family has a history of thalassaemia, if you or your partner have been identified as carriers, or if you are seeking specialist care for a child with thalassaemia major, our Haemato-Oncology and Bone Marrow Transplant team is here to guide you.

To book an appointment with our specialists, simply call +91-11-4702 2222 (Rohini) / +91-11-4582 2222 (Niti Bagh, South Delhi). Book online at care.rgcirc.org | Download the RGCI Care app on iOS and Android

OPD Hours: Monday to Saturday, 9:00 AM to 5:00 PM | Emergency Services: 24×7 at both campuses

Frequently Asked Questions (FAQs)

Can thalassaemia be cured?

Thalassaemia major can be potentially cured through allogeneic bone marrow or stem cell transplantation, where defective marrow is replaced with healthy donor marrow. Outcomes are best in younger patients with a matched sibling donor and minimal organ damage. Gene therapy is an emerging option, with Betibeglogene autotemcel showing the ability to achieve transfusion independence in clinical studies. For patients who are not suitable for transplant, thalassaemia is managed through lifelong transfusions and iron chelation therapy.

Are thalassaemia and sickle cell disease the same?

No. Both are inherited haemoglobin disorders but differ in cause and presentation. Thalassaemia involves reduced or absent production of haemoglobin chains, leading to chronic anaemia. Sickle Cell Disease is caused by a structural defect in haemoglobin, resulting in rigid, crescent-shaped red blood cells that can block blood flow and cause painful episodes. Some individuals may inherit both conditions, known as sickle-beta thalassaemia.

Does thalassaemia affect pregnancy?

Yes. Women with thalassaemia major or intermedia may face increased risks such as anaemia, cardiac strain, and hormonal imbalances, requiring coordinated care by haematology and obstetric teams. In addition, if both partners are carriers, each pregnancy carries a one in four risk of the child having thalassaemia major. Prenatal testing options are available to determine the condition during pregnancy.

Does a CBC test detect thalassaemia?

A complete blood count can suggest thalassaemia by showing low mean corpuscular volume and mean corpuscular haemoglobin, which indicate microcytic anaemia. However, it does not confirm the diagnosis. Confirmation requires haemoglobin electrophoresis or high-performance liquid chromatography to detect characteristic changes such as elevated haemoglobin A2 levels. Genetic testing may be used for definitive confirmation.

Are thalassaemia carriers at risk?

Carriers, also known as thalassaemia minor, usually lead normal, healthy lives with little or no symptoms apart from mild anaemia. They do not require treatment. The main concern is reproductive risk, as two carriers have a 25 percent chance of having a child with thalassaemia major. Carrier screening before marriage or pregnancy helps in making informed decisions.

What food is good for thalassaemia?

A balanced diet is important for overall health while avoiding excess iron intake. Foods rich in calcium, such as dairy products and leafy greens, support bone health. Folate-rich foods such as lentils, legumes, and fortified grains help in red blood cell production. Iron-rich foods and Vitamin C intake alongside iron-containing meals should be moderated in regularly transfused patients. Consulting a clinical dietician is recommended for personalised guidance.

Where did thalassaemia originate?

Thalassaemia is believed to have originated in regions where malaria was common, as carriers have some natural protection against severe malaria. The name comes from the Greek word “thalassa,” meaning sea, as the condition was first identified in populations around the Mediterranean region in the early 20th century. Today, it is found across the Mediterranean, Middle East, South Asia, South-East Asia, and Africa.

Is thalassaemia autosomal recessive?

Yes. Both alpha and beta thalassaemia follow an autosomal recessive inheritance pattern. A child must inherit one defective gene from each parent to develop the severe form. Individuals with only one defective gene are carriers and can pass the gene to their children.